In a filing, Intellia Therapeutics Inc revealed its President and CEO LEONARD JOHN M unloaded Company’s shares for reported $0.84 million on Dec 11 ’25. In the deal valued at $9.49 per share,88,146 shares were sold. As a result of this transaction, LEONARD JOHN M now holds 1,038,928 shares worth roughly $10.11 million.
Then, LEONARD JOHN M bought 88,146 shares, generating $822,402 in total proceeds.
Before that, Schultes Birgit C sold 31 shares. Intellia Therapeutics Inc shares valued at $539 were divested by the EVP, Chief Scientific Officer at a price of $17.38 per share. As a result of the transaction, Schultes Birgit C now holds 105,184 shares, worth roughly $1.02 million.
Wolfe Research downgraded its Intellia Therapeutics Inc [NTLA] rating to a Peer perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “an In-line”. JP Morgan also remained covering NTLA and has decreased its forecast on November 07, 2025 with a “an Underweight” recommendation from previously “Neutral” rating. RBC Capital Mkts revised its rating on October 28, 2025. It rated NTLA as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of NTLA
On Tuesday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock jump 3.84% to $9.73. Over the last five days, the stock has gained 6.46%. Intellia Therapeutics Inc shares have fallen nearly -20.38% since the year began. Nevertheless, the stocks have risen 8.23% over the past one year. While a 52-week high of $28.25 was reached on 01/06/26, a 52-week low of $5.90 was recorded on 01/02/26.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 9.30, which if violated will result in even more drops to 8.88. On the upside, there is a resistance level at 10.16. A further resistance level may holdings at 10.60.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-12-15, growing by 0.34 million shares to a total of 40.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 40.24 million shares. There was a rise of 0.84%, which implies that there is a positive sentiment for the stock.
